The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Axonal pathology in multiple sclerosis: relationship to neurologic disability
Abstract
In this review, data is summarized supporting the hypothesis that axonal loss is a major pathologic process responsible for irreversible neurologic disability in patients with multiple sclerosis. Pathologic studies implicate inflammatory demyelination as a principal cause of axonal transection and subsequent axonal degeneration. Axonal degeneration caused by chronic demyelination in the absence of active inflammation may also contribute to progressive disability in the later stages of the disease. Studies using magnetic resonance spectroscopy suggest that axonal loss begins at the onset of the disease, and studies using magnetic resonance imaging have documented brain atrophy in the earliest stages of multiple sclerosis. Brain atrophy increases during the relapsing-remitting disease stage without concurrent disability progression. This suggests that compensatory mechanisms maintain neurologic function, despite progressive brain tissue loss during the early stages of the disease. Beyond a threshold, however, further axonal loss leads to continuously progressive neurologic disability. We hypothesize that the rate and extent of axonal loss during relapsing-remitting multiple sclerosis determines when a patient enters the secondary progressive stage of the disease. This view of disease pathogenesis has several important implications. First, surrogate markers of axonal loss are needed to monitor the disease process for patient care and for clinical trials. We propose brain parenchymal fraction, a precise measure of whole-brain atrophy, as an attractive candidate for this purpose. Second, disease-modifying therapy should be used early in multiple sclerosis patients, before extensive axonal loss has occurred. Third, neuroprotective drugs should be tested in combination with anti-inflammatory drugs in multiple sclerosis patients. Finally, studies of the time course of axonal loss, and its mechanisms are critical for effective therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationRaff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.
Koo, E. H., Sisodia, S. S., Archer, D. R., Martin, L. J., Weidemann, A., Beyreuther, K., Fischer, P., Masters, C. L., & Price, D. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1561 · Cited by 733
Losseff, N. A., Webb, S. L., O'Riordan, J. I., Page, R., Wang, L., Barker, G. J., Tofts, P. S., McDonald, W. I., Miller, D. H., & Thompson, A. J. (1996) · Brain · doi:10.1093/brain/119.3.701 · Cited by 643
Nishiyama, A., Lin, X.-H., Giese, N., Heldin, C.-H., & Stallcup, W. B. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960201)43:3<299::aid-jnr5>3.0.co;2-e · Cited by 630
Wolswijk, G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00601.1998 · Cited by 562
Endogenous progenitors remyelinate demyelinated axons in the adult CNS
Gensert, J. M., & Goldman, J. E. (1997) · Neuron · doi:10.1016/s0896-6273(00)80359-1 · Cited by 544
Myelin-Associated Glycoprotein Is a Myelin Signal that Modulates the Caliber of Myelinated Axons
Yin, X., Crawford, T. O., Griffin, J. W., Tu, P.-H., Lee, V. M.-Y., Li, C., Roder, J., & Trapp, B. D. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-01953.1998 · Cited by 496
Self-citationIdentification of an adult-specific glial progenitor cell
Wolswijk, G., & Noble, M. (1989) · Development · doi:10.1242/dev.105.2.387 · Cited by 485
Cited by
Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water
Song, S.-K., Sun, S.-W., Ramsbottom, M. J., Chang, C., Russell, J., & Cross, A. H. (2002) · NeuroImage · doi:10.1006/nimg.2002.1267 · Cited by 2,582
Song, S.-K., Sun, S.-W., Ju, W.-K., Lin, S.-J., Cross, A. H., & Neufeld, A. H. (2003) · NeuroImage · doi:10.1016/j.neuroimage.2003.07.005 · Cited by 1,738
Demyelination increases radial diffusivity in corpus callosum of mouse brain
Song, S.-K., Yoshino, J., Le, T. Q., Lin, S.-J., Sun, S.-W., Cross, A. H., & Armstrong, R. C. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.01.028 · Cited by 1,658
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Offen, D., Gilgun-Sherki, Y., & Melamed, E. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0348-9 · Cited by 638
Metadata
- Authors
- Trapp, B. D., Ransohoff, R., & Rudick, R.
- Venue
- Current Opinion in Neurology
- Published
- 1999-06
- Volume
- 12
- Issue
- 3
- Pages
- 295-302
- ISSN
- 1350-7540 (ISSN-L)
- OpenAlex
- W2325735106
- Cited by
- 475
- References
- 40
- FWCI
- 10.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Axonal pathology in multiple sclerosis: relationship to neurologic disability. https://app.cochat.ai/papers/10.1097/00019052-199906000-00008
- The paper
- Trapp, B. D., Ransohoff, R., & Rudick, R. (1999). Axonal pathology in multiple sclerosis: relationship to neurologic disability. Current Opinion in Neurology. https://doi.org/10.1097/00019052-199906000-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.